EUVIMEDEUVIMED entdecken
Crossref

Mechanism, Challenges, and Progresses of Chimeric Antigen Receptors T-cell Cancer Therapy

Adem Hussein, Bedaso Mammo

Journal of Cellular Immunology · 2024

DOI: 10.33696/immunology.6.190 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular Immunology, 2024. Verfasst von Adem Hussein und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a deadly disease and affects everyone at any level of age. Many people lose hope once they are diagnosed with cancer. This is because there is no effective treatment for it. Till the end of the 19th century, researchers across the world were eager to design effective remedies for this decapitating phenomenon and designed so many interventions even though nothing is compensatory for a malignant tumor; in some cases, the side effects overwhelm the benefits. These interventions were surgery, irradiation, and chemotherapy like immune checkpoint inhibitors. The research in the early 20th century has come up with a very promising remedy for cancer at clinical trials and even some of which have been approved by various drug quality control agencies such as the Food and Drug Administration (FDA). This is the Chimeric Antigen Receptor T-cell (CAR T-cell) Therapy. For this, T-cells are collected from the patient and genetically engineered, with the use of a viral vector, to express a CAR that is specific to an antigen expressed on a tumor cell. Then, the modified T-cells are expanded in the laboratory and re-infused into the patient to target and destroy all cells that express the tumor-associated antigen, to act as surveillance after it is fully transplanted. Its clinical trial attests a very good efficacy, safety, complete remission, and perdurability of the engineered CAR T-cells. However, there is still undiscovered knowledge regarding the full applications of CAR T-cell therapy especially for solid cancers, indicating the need for researchers’ efforts to end cancer globally.

Zitieren

APA

Hussein, A., & Mammo, B. (2024). Mechanism, Challenges, and Progresses of Chimeric Antigen Receptors T-cell Cancer Therapy. Journal of Cellular Immunology. https://doi.org/10.33696/immunology.6.190

Vancouver

Hussein A, Mammo B. Mechanism, Challenges, and Progresses of Chimeric Antigen Receptors T-cell Cancer Therapy. Journal of Cellular Immunology. 2024. doi:10.33696/immunology.6.190

BibTeX
@article{Hussein2024,
  author = {Hussein, Adem and Mammo, Bedaso},
  title = {Mechanism, Challenges, and Progresses of Chimeric Antigen Receptors T-cell Cancer Therapy},
  journal = {Journal of Cellular Immunology},
  year = {2024},
  doi = {10.33696/immunology.6.190}
}
Kostenlos starten →